Dysarthria in amyotrophic lateral sclerosis: A review

Amyotrophic Lateral Sclerosis

Volumn 11, Issue 1-2, 2010, Pages 4-15

  Tomik, Barbara ^a   Guiloff, Roberto J ^b  

^a JAGIELLONIAN UNIVERSITY   (Poland)

^b CHARING CROSS HOSPITAL   (United Kingdom)

Author keywords

ALS; Bulbar palsy; Dysarthria; MND

Indexed keywords

AMITRIPTYLINE; ATROPINE; BACLOFEN; BOTULINUM TOXIN; BOTULINUM TOXIN A; GLYCOPYRRONIUM BROMIDE; PYRIDOSTIGMINE; SCOPOLAMINE; TIZANIDINE;

AMYOTROPHIC LATERAL SCLEROSIS; CLINICAL ASSESSMENT; CLINICAL FEATURE; COGNITIVE DEFECT; CRANIAL NEUROPATHY; CRYOTHERAPY; DIFFERENTIAL DIAGNOSIS; DRUG DOSE INCREASE; DYSARTHRIA; ENT EXAMINATION; FLACCID PARALYSIS; FRONTOTEMPORAL DEMENTIA; HEARING TEST; HUMAN; HYPERSALIVATION; LANGUAGE DISABILITY; NEUROIMAGING; NEUROLOGIC DISEASE; PALATOPLASTY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROSTHESIS; REVIEW; SPASMODIC DYSPHONIA; SPASTICITY; SPEECH; SPEECH ANALYSIS; SPEECH DISORDER; SPEECH THERAPY; TRACHEOSTOMY;

AMYOTROPHIC LATERAL SCLEROSIS; DYSARTHRIA; HUMANS; SPEECH THERAPY;

EID: 77649322309     PISSN: 17482968     EISSN: 1471180X     Source Type: Journal    
DOI: 10.3109/17482960802379004     Document Type: Review

References (114)

1. Borasio GD, Voltz R. Palliative care in amyotrophic lateral sclerosis. J Neurol. 1997;(Suppl 4):S11-7.
2. Borasio GD, Voltz R, Miller RG. Palliative care in amyotrophic lateral sclerosis. Neurol Clin. 2001;19:829-47.
3. Leigh PN, Abrahams S, Al-Chalabi A, Ampong MA, Goldstein LH, Johnson J, et al. The management of motor neuron disease. J Neurol Neurosurg Psychiatry. 2003; 74(Suppl 4):32-47.
4. Watts CR, Vanryckeghem M. Laryngeal dysfunction in amyotrophic lateral sclerosis: a review and case report. BMC Ear Nose Throat Disord. 2001;1:1.
5. Yorkston KM. Treatment efficacy: dysarthria. J Speech Hear Res. 1996;36:S46-57.
6. Bach JR. Amyotrophic lateral sclerosis: communication status and survival with ventilatory support. Am J Phys Med. 1993;72:343-9.
7. Mitsumoto H, Del Bene M. Improving the quality of life for people with ALS: the challenge ahead. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1:329-36.
8. Sellars C, Hughes T, Langhorne P. Speech and language therapy for dysarthria due to non-progressive brain damage. Cochrane Database Syst Rev. 2005;20:CD002088.
9. Pahwa R, Factor SA, Lyons KE, Ondo WG, Gronseth G, Bronte-Stewart H, et al. Practice Parameter: treatment of Parkinson's disease with motor fluctuations and dyskinesia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006;66:983-95.
10. Kent RD. Research on speech motor control and its disorders: a review and prospective. J Commun Disord. 2000;33:391-427.
11. Yorkston KM, Strand E, Miller R, Hillel A, Smith K. Speech deterioration in amyotrophic lateral sclerosis: implications for the timing of intervention. J Med Speech Lang Pathol. 1993;1:35-46.
12. Traynor BJ, Codd MB, Corr B, Forde C, Frost E, Hardiman O. Clinical features of amyotrophic lateral sclerosis according to the El Escorial and Airlie House diagnostic criteria: a population-based study. Arch Neurol. 2000; 57:1171-6.
13. Darley F, Aronson A, Brown J. Clusters of deviant speech dimensions in the dysarthrias. J Speech Hear Res. 1969; 12:462-96.
14. Darley F, Aronson A, Brown J. Differential diagnostic patterns of dysarthria. J Speech Hear Res. 1969;12:246-69.
15. Kent RD, Kent JF, Weismer G. What dysarthrias can tell us about the neural control of speech. J Phon. 2000;28:273- 302.
16. Roth CR, Glaze LE, Goding GS Jr, David WS. Spasmodic dysphonia symptoms as initial presentation of amyotrophic lateral sclerosis. J Voice. 1996;10:362-7.
17. Strong MJ, Grace GM, Orange JB, Leeper HA. Cognition, language, and speech in amyotrophic lateral sclerosis: a review. J Clin Exp Neuropsychol. 1996;18:291-303.
18. Okuda B, Kodama N, Kawabata K, Tachibana H, Sugita M, Corneomandibular reflex in ALS. Neurology. 1999; 52:1699-701.
19. Mitsumoto H, Chad DA, Pioro EK. Speech and communication management. In: Mitsumoto H, Chad DA, Pioro EK, editors. Amyotrophic Lateral Sclerosis. New York: FA Davis Co, 1998. p. 405-20.
20. McGuirt WF, Blalock D. The otolaryngologist's role in the diagnosis and treatment of amyotrophic lateral sclerosis. Laryngoscope. 1980;90:1496-501.
21. Hillel A, Dray T, Miller R, Konikow N, Strande E, Browne J. Presentation of ALS to the otolaryngologist/ head and neck surgeon: getting to the neurologist. Neurology. 53. 1999;(Suppl 5):S22-5.
22. Chen A, Garrett CG. Otolaryngological presentations of amyotrophic lateral sclerosis. Otolaryngol Head Neck Surg. 2005;132:500-4.
23. Klasner E, Yorkston K, Strand E. Patterns of perceptual features in speakers with ALS: a preliminary study of prominence and intelligibility considerations. J Med Speech Langue Pathol. 1999;7:117-25.
24. Janzen VD, Rae RE, Hudson AJ. Otolaryngological manifestations of amyotrophic lateral sclerosis. J Otolaryngol. 1988;17:41-2.
25. Aronson AE, Ramig LO, Winholtz WS, Silber SR. Rapid voice tremor, or 'flutter', in amyotrophic lateral sclerosis. Ann Otol Rhinol Laryngol. 1992;101:511-8.
26. Tomik J, Tomik B, Partyka D, Skladzien J, Szczudlik A. Profile of laryngological abnormalities in patients with amyotrophic lateral sclerosis. J Laryngol Otol. 2007;26:1-6.
27. Ball LJ, Willis A, Beukelman DR, Pattee GL. A protocol for identification of early bulbar signs in ALS. J Neurol Sci. 2001;191:43-53.
28. Turner GS, Tjaden K, Weismer G. The influence of speaking rate on vowel space and speech intelligibility for individuals with amyotrophic lateral sclerosis. J Speech Hear Res. 1995;38:1001-13.
29. Weismer G, Laures JS, Jeng JY, Kent RD, Kent JF. Effect of speaking rate manipulations on acoustic and perceptual aspects of dysarthria in ALS. Folia Phoniatr. 2000;52:201- 19.
30. Kent RD, Sufit RL, Rosenbek JC, Kent JF, Weismer G, Martin RE, et al. Speech deterioration in amyotrophic lateral sclerosis: a cases study. J Speech Hear Res. 1991; 34:1269-75.
31. Caruso AJ, Burton EK. Temporal acoustic measures of dysarthria associated with amyotrophic lateral sclerosis. J Speech Hear Res. 1987;30:80-7.
32. Turner GS, Tjaden K, Weismer G. The influence of speaking rate on vowel space and speech intelligibility for individuals with amyotrophic lateral sclerosis. J Speech Hear Res. 1995;38:1001-13.
33. Hillel AD, Miller RM, Yorkston K, McDonald E, Norris FH, Konikow N. Amyotrophic lateral sclerosis severity scale. Neuroepidemiology. 1989;8:142-5.
34. Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci. 1999;169:13-21.
35. Appel V, Stewart SS, Smith G, Appel SH. A rating scale for amyotrophic lateral sclerosis: description and preliminary experience. Ann Neurol. 1987;22:328-33.
36. Norris FH Jr, Calanchini PR, Fallat RJ, Panchari S, Jewett B. The administration of guanidine in amyotrophic lateral sclerosis. Neurology. 1974;24:721-8.
37. Goonetilleke A, Guiloff RJ. Accuracy, reproducibility and variability of quantitative assessments of bulbar and respiratory function in motor neuron disease. J Neurol Sci. 1994;124(Suppl):64-6.
38. Goonetilleke A, Guiloff RJ. Continuous response variable trial design in motor neuron disease: long-term treatment with a TRH analogue (RX77368). J Neurol Neurosurg Psychiatry. 1995;58:201-8.
39. Guiloff RJ, Modarres-Sadeghi H, Rogers H. Motor neuron disease: aims and assessment methods in trial design. In: Clifford-Rose F, editor. Methodological Problems in Clinical Neurologic Trials. Vol.1. Amyotrophic Lateral Sclerosis. New York: Demos; 1990. p. 19-31.
40. Guiloff RJ, Goonetilleke A. Longitudinal clinical assessments in motor neuron disease. Relevance to clinical trials. In: Clifford-Rose F, editor. ALS- From Charcot to the Present and into the Future. London: Smith-Gordon/ Nishimura, 1994. p. 73-82.
41. Guiloff RJ, Goonetilleke A. Natural history of amyotrophic lateral sclerosis. Observations with the Charing Cross Amyotrophic Lateral Sclerosis Rating Scales. Adv Neurol. 1995;68:185-98.
42. Miller RG, Munsat TL, Swash M, Brooks BR. Consensus guidelines for the design and implementation of clinical trials in ALS. WFN Research Committee on Motor Neuron Diseases. J Neurol Sci. 1999;169:2-12.
43. Dworkin JP. Tongue strength measurement in patients with amyotrophic lateral sclerosis: qualitative versus quantitative procedures. Arch Phys Med Rehab. 1980;61:422-4.
44. Carrow E, Rivera V, Mauldin M, Shamblin L. Deviant speech characteristic in motor neuron disease. Arch Otolaryngol Head Neck Surg. 1974;100:212-8.
45. Riddel J, McCauley RJ, Mulligan M, Tandan R. Intelligibility and phonetic contrast errors in highly intelligible speakers with amyotrophic lateral sclerosis. J Speech Hear Res. 1995;38:304-14.
46. Tomik B, Glodzik-Sobanska L, Lechwacka A, Bala-Slodowska M, Kolasa M, Szczudlik A. The application of dysarthria profile tests in ALS patients for the detection of speech disturbances. Neurol Neurochir Pol. 2000;34: 269-79.
47. Robertson SJ, ed. Robertson Dysarthria Profile. Bicester: Winslow Press; 1982.
48. Langmore SE, Lehman ME. Physiological deficits in the orofacial system underlying dysarthria in amyotrophic lateral sclerosis. J Speech Hear Res. 1994;37:28-37.
49. Kent JF, Kent RD, Rosenbek JC, Weismer G, Martin RE, Sufit RL, et al. Quantitative description of dysarthria in women with amyotrophic lateral sclerosis. J Speech Hear Disord. 1992;3:723-33.
50. Weismer G, Martin R, Kent RD, Kent JF. Formant trajectory characteristics of males with amyotrophic lateral sclerosis. J Acoust Soc Am. 1992;1:1085-98.
51. Tomik B, Krupinski J, Glodzik-Sobanska L, Bala-Slodowska M, Wszolek W, Kusiak M, et al. Acoustic analysis of dysarthria profile in ALS patients. J Neurol Sci. 1999; 169:35-42.
52. Robert D, Pouget J, Giovanni A, Azulay JP, Triglia JM. Quantitative voice analysis in the assessment of bulbar involvement in amyotrophic lateral sclerosis. Acta Otolaryngol. 1999;119:724-31.
53. Weismer G, Kent RD, Hodge M, Martin R. The acoustic signature for intelligibility test words. J Acoust Soc Am. 1988;84:1281-91.
54. Silbergleit AK, Johnson AF, Jacobson BH. Acoustic analysis of voice in individuals with amyotrophic lateral sclerosis and perceptually normal vocal quality. J Voice. 1997;11:222-31.
55. Ramig L, Scherer R, Klasner E, Titz, Horii Y. Acoustic analysis of voice in amyotrophic lateral sclerosis: a longitudinal case study. J Speech Hear Disord. 1990;55:2-14.
56. Mulligan M, Carpenter J, Riddel J, Delaney MK, Badger G, Krusinski P, et al. Intelligibility and acoustic characteristics of speech in amyotrophic lateral sclerosis. J Speech Hear Res. 1994;37:496-503.
57. Turner GS, Tjaden K. Acoustic differences between content and function words in amyotrophic lateral sclerosis. J Speech Lang Hear Res. 2000;43:769-81.
58. Enderby PM. Frenchay Dysarthria Assessment. Br J Disord Commun. 1980;15:165-73.
59. Yorkston KM, Beukelman DR. Communication efficiency of dysarthric speakers as measured by sentence intelligibility and speaking rate. J Speech Hear Res. 1981;46:296-301.
60. Strand EA, Miller RM, Yorkston KM, Hillel AD. Management of oral-pharyngeal dysphagia symptoms in amyotrophic lateral sclerosis. Dysphagia. 1996;11:129-39.
61. Cobble M. Language impairment in motor neuron disease. J Neurol Sci. 1998;(Suppl 1):S47-52.
62. Abrahams S, Leigh PN, Harvey A, Vythelingum GN, Grise D, Goldstein LH. Verbal fluency and executive dysfunction in amyotrophic lateral sclerosis (ALS). Neuropsychologia. 2000;38:734-47.
63. Bak TH, Hodges JR. The effects of motor neuron disease on language: further evidence. Brain Lang. 2004;89:354-61.
64. Caselli RJ, Windebank AJ, Petersen RC, Komori T, Parisi JE, Okazaki H, et al. Rapidly progressive aphasic dementia and motor neuron disease. Ann Neurol. 1993;33:200-7. (Pubitemid 23039929)
65. Rakowicz WP, Hodges JR. Dementia and aphasia in motor neuron disease: an under-recognized association? J Neurol Neurosurg Psychiatry. 1998;65:881-9.
66. Neary D, Snowden JS, Mann DM, Northen B, Goulding PJ, Macdermott N. Frontal lobe dementia and motor neuron disease. J Neurol Neurosurg Psychiatry. 1990; 53:23-32.
67. Gray's Anatomy, 38th edn. London: Churchill Livingstone; 1995. pp 1230-58.
68. Jankowska E, Tanaka R. Neuronal mechanism of the disynaptic inhibition evoked in primate spinal motor neurons from the corticospinal tract. Brain Res. 1974;75:163-6.
69. Lawyer T, Netsky MG. Amyotrophic lateral sclerosis: a clinicoanatomic study of 53 cases. AMA Arch Neurol Psychiatry. 1953;69:171-92.
70. Carpenter RJ, McDonald TJ, Howard FM. The otolaryngological presentation of amyotrophic lateral sclerosis. J Otol Rhinol Laryngol. 1978;86:479-84.
71. De Paul R, Abbs JH, Caligiuri M, Gracco VL, Brooks BR. Hypoglossal, trigeminal, and facial motor neuron involvement in amyotrophic lateral sclerosis. Neurology. 1988;38:281-3.
72. Dworkin JP. Tongue strength measurement in patients with amyotrophic lateral sclerosis: qualitative versus quantitative procedures. Arch Phys Med Rehab. 1980;61:422-4.
73. De Paul R, Brooks BR. Multiple orofacial indices in amyotrophic lateral sclerosis. J Speech Hear Res. 1993; 36:1158-67.
74. Kent RD, Kent JF, Weismer G, Sufit RL, Rosenbek JC, Martin RE, et al. Impairment of speech intelligibility in men with amyotrophic lateral sclerosis. J Speech Hear Disord. 1990;55:721-8.
75. Cha CH, Pattern BM. Amyotrophic lateral sclerosis: abnormalities of the tongue on magnetic resonance imaging. Ann Neurol. 1989;25:468-72.
76. Andersen PM, Borasio GD, Dengler R, Hardiman O, Kollewe K, Leigh PN, et al. EFNS task force on management of amyotrophic lateral sclerosis: guidelines for diagnosing and clinical care of patients and relatives. Eur J Neurol. 2005;12:921-38.
77. Yorkston KM. Management of dysarthria in amyotrophic lateral sclerosis. Geriatr Aging. 2002;5:38-41.
78. Murphy J. Communication strategies of people with ALS and their partners. Amyotroph Lateral Scler Other Motor Neuron Disord. 2004;5:121-6.
79. Langton-Hewer R. The management of motor neuron disease. In: Leigh PN, Swash M, editors. Motor Neuron Disease-Biology and Management. London: Springer- Verlag, 1995. p. 375-406.
80. McHenry M, Whatman J, Pou A. The effect of botulinum toxin A on the vocal symptoms of spastic dysarthria: a case study. J Voice. 2002;16:124-31.
81. Holden PK, Vokes DE, Taylor MB, Till JA, Crumley RL. Long-term botulinum toxin dose consistency for treatment of adductor spasmodic dysphonia. Ann Otol Rhinol Laryngol. 2007;116:891-6.
82. Watts CR, Truong DD, Nye C. Evidence for the effectiveness of botulinum toxin for spasmodic dysphonia from high-quality research designs. J Neural Transm. 2008;115: 625-30.
83. Casserly P, Timon C. Botulinum toxin A injection under electromyographic guidance for treatment of spasmodic dysphonia. J Laryngol Otol. 2008;122:52-6.
84. Watts C, Nye C, Whurr R. Botulinum toxin for treating spasmodic dysphonia (laryngeal dystonia): a systematic Cochrane review. Clin Rehabil. 2006;20:112-22.
85. Denys EH, Norris FH. Amyotrophic Lateral Sclerosis. Impairment of neuromuscular transmission. Arch Neurol. 1979;36:202-5.
86. Cui LY, Liu MS, Tang XF. Single fibre electromyography in 78 patients with amyotrophic lateral sclerosis. Chin Med J. 2004;117:1830-3.
87. Giess R, Naumann M, Werner E, Riemann R, Beck M, Puls I. Injections of botulinum toxin A into the salivary glands improve sialorrhoea in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2000;69:121-3.
88. Verma A, Steele J. Botulinum toxin improves sialorrhoea and quality of living in bulbar amyotrophic lateral sclerosis. Muscle Nerve. 2006;34:235-7.
89. Manrique D. Application of botulinum toxin to reduce the saliva in patients with amyotrophic lateral sclerosis. Rev Bras Otorrinolaringol (Engl Ed). 2005;71:566-9.
90. Meijer JW, van Kuijk AA, Geurts AC, Schelhaas HJ, Zwarts MJ. Acute deterioration of bulbar function after botulinum toxin treatment for sialorrhoea in amyotrophic lateral sclerosis. Am J Phys Med Rehabil. 2008;87:321-4.
91. Borasio GD, Shaw PJ, Hardiman O, Ludolph AC, Sales Luis ML, Silani V. European ALS Study Group. Standards of palliative care for patients with amyotrophic lateral sclerosis: results of a European survey. Amyotroph Lateral Scler Other Motor Neuron Disord. 2001;2:159-64.
92. Gelinas D, Miller RG. A treatable disease: a guide to the management of amyotrophic lateral sclerosis. In: Brown RHJr, Meininger V, Swash M, editors. Amyotrophic Lateral Sclerosis. London: Martin Dunitz, 2000. p. 405-21.
93. Esposito SJ, Mitsumoto H, Shanks M. Use of palatal lift and palatal augmentation prostheses to improve dysarthria in patients with amyotrophic lateral sclerosis: a case series. J Prosthet Dent. 2000;83:90-8.
94. Gonzalez JB, Aronson AE. Palatal lift prosthesis for treatment of anatomical and neurological palatopharyngeal insufficiency. Cleft Palate J. 1970;7:91-103.
95. Enderby P, Hathorn IS, Servant S. Use of intra-oral appliances in the management of acquired velopharyngeal disorders. British Dental J. 1984;157:157-9.
96. Ono T, Hamamura M, Honda K, Nokubi T. Collaboration of a dentist and speech-language pathologist in the rehabilitation of a stroke patient with dysarthria: a case study. Gerodontology. 2005;22:116-9.
97. Suwaki M, Nanba K, Ito E, Kumakura I, Minagi S. Nasal speaking valve: a device for managing velopharyngeal incompetence. J Oral Rehabil. 2008;35:73-7.
98. Ball LJ, Beukelman DR, Pattee GL. Communication effectiveness of individuals with amyotrophic lateral sclerosis. J Commun Disord. 2004;37:197-215.
99. ALS Association (ALSA) www.alsa.org.
100. Nijboer F, Sellers EW, Mellinger J, Jordan MA, Matuz T, Furdea A. AP300-based brain-computer interface for people with amyotrophic lateral sclerosis. Clin Neurophysiol. 2008;119:1909-16.
101. American Thoracic Society Documents . Respiratory care of the patient with Duchenne Muscular Dystrophy. ATS Consensus Statement. Am J Respir Crit Care Med. 2004;170:456-65.
102. Polkey MI, Lyall RA, Moxham J, Liegh PN. Respiratory aspects of neurological disease. J Neurol Neurosurg Psychiatry. 1999;66:5-15.
103. Sherman MS, Paz HL. Review of respiratory care of the patient with amyotrophic lateral sclerosis. Respiration. 1994;61:61-7.
104. Guger C, Ramoser H, Pfurtscheller G. Real-time EEG analysis with subject-specific spatial patterns for a braincomputer interface (BCI). IEEE Trans Neural Syst Rehabil Eng. 2000;8:447-56.
105. Kubler A, Kotchoubey B, Kaiser J, Wolpaw JR, Birbaumer N. Brain-computer communication: unlocking the locked in. Psychol Bull. 2001;127:358-75.
106. Neumann N, Kublerm A. Training locked-in patients: a challenge for the use of brain-computer interfaces. IEEE Trans Neural Syst Rehabil Eng. 2003;11:169-72.
107. Neumann N, Hinterberger T, Kaiser J, Leins U, Birbaumer N, Kubler A. Automatic processing of self-regulation of slow cortical potentials: evidence from brain-computer communication in paralysed patients. Clin Neurophysiol. 2004;115:628-35.
108. Kaiser J, Perelmouter J, Iversen IH, Neumann N, Ghanayim N, Hinterberger T, et al. Self-initiation of EEG-based communication in paralysed patients. Clin Neurophysiol. 2001;112:551-4.
109. Rohde MM, BeMent SL, Huggins JE, Levine SP, Kushwaha RK, Schuh LA. Quality estimation of subdurally recorded, event-related potentials based on signal-to-noise ratio. IEEE Trans Biomed Eng. 2002;49:31-40.
110. Abrahams S, Leigh PN, Harvey A, Vythelingum GN, Grisé D, Goldstein LH. Verbal fluency and executive dysfunction in amyotrophic lateral sclerosis (ALS). Neuropsychologia. 2000;38:734-47.
111. Bak TH, Hodges JR. The effects of motor neuron disease on language: further evidence. Brain Lang. 2004;89:354-61.
112. Abrahams S, Leigh PN, Goldstein LH. Cognitive change in ALS: a prospective study. Neurology. 2005;64:1222-6.
113. Flaherty-Craig C, Eslinger P, Stephens B, Simmons Z. A rapid screening battery to identify frontal dysfunction in patients with ALS. Neurology. 2006;67:2070-2.
114. Lomen-Hoerth C, Murphy J, Langmore S, Kramer JH, Olney RK, Miller B. Are amyotrophic lateral sclerosis patients cognitively normal? Neurology. 2003;60:1094-7.